-
The production capacity of the whole scorpion is limited, and the key to the market outlook depends on capital strength!
Time of Update: 2022-04-18
The main reason for the rise of the Quan Scorpion market in July 2020 was that the epidemic caused the country to issue a ban on wild animals, coupled with the general increase in the price of Chinese medicinal materials, capital forces took advantage of the situation to participate .
-
New crown antigen detection reagents have been temporarily included in medical insurance in many places!
Time of Update: 2022-04-18
Recently, the "Notice on Effectively Doing a Good Job in the Current Epidemic Prevention and Control Medical Security" issued by the Office of the National Medical Security Administration proposed that the new coronavirus antigen detection reagents and corresponding detection items should be temporarily included in the province's basic medical insurance medical service item catalog according to procedures .
-
Two inhalants were approved on the same day, and Chia Tai Tianqing won the first domestic company
Time of Update: 2022-04-18
Recently, the official website of the State Food and Drug Administration showed that Chia Tai Tianqing's inhalation methacholine and Jiangsu Changtai Pharmaceutical's hydrochloric acid Levosalbutamol aerosol inhalation solution was approved on the same day as the imitation Category 3, which is regarded as over-evaluation .
-
New regulations for drug retail distribution: drugs sold in these situations can be returned
Time of Update: 2022-04-18
In addition, when the medicine is delivered, if the consumer refuses to sign for it due to the damaged delivery packaging, damaged seal, inconsistent delivery information and quality problems of the medicine in the package, the delivery person shall return it to the pharmaceutical retail enterprise in accordance with the "Quality Management Practice for Pharmaceutical Operations".
-
Where are the growth drivers of local CRO/CDMO companies?
Time of Update: 2022-04-18
From a business perspective, the company said that there are several major factors driving the company's performance growth in 2021: first, the production business revenue has achieved significant growth; second, new non-new crown comprehensive projects have driven revenue and market share; third, the implementation of existing and New orders brought by new crown projects; fourth, implement the strategy of "follow and win molecules", add more late-stage clinical projects, and improve recent income; fifth, increase capacity utilization and operational efficiency .
-
Imports of medicinal materials ushered in explosive growth in the first three quarters of 2021
Time of Update: 2022-04-18
According to China Customs data, in the first three quarters of 2021, the total export value of Chinese herbal medicines and decoction pieces in China was US$970 million, a year-on-year increase of 2.
-
The 1 billion large variety Sichuan Huiyu Levetiracetam Injection Concentrated Solution is about to be approved
Time of Update: 2022-04-18
On March 30, Sichuan Huiyu Pharmaceutical's 4 types of generic marketing application for levetiracetam injection concentrated solution has completed the approval process, waiting for the official announcement of the results .
Figure 3: Approved products of Sichuan Huiyu Pharmaceutical from 2022 to the present Source: new version database of Minet.
-
2021 National ADR Monitoring Annual Report Released
Time of Update: 2022-04-18
From the overall situation, the proportion of traditional Chinese medicine in the total adverse reaction/event reports in 2021 will show a downward trend, but it is still necessary to pay attention to safe drug use .
-
Two ministries and commissions: Organize the centralized procurement of high-value medical consumables (artificial joints)
Time of Update: 2022-04-18
The opinion proposes that the selected products in the centralized procurement of artificial joints shall be paid with the selected price including accompanying service fees as the payment standard, which shall be included in the scope of medical insurance payment, and the medical insurance fund shall pay according to the prescribed proportion .
-
The leader of Nanyao is attacking innovative drugs, and 5 new drugs of category 1 are already on the way
Time of Update: 2022-04-18
Among them, Sildenafil Citrate Tablets are the largest sales variety of Guangzhou Baiyunshan Da Nan Medicine segment, with annual revenue of 988 million yuan in 2021 .
-
In the next five years, my country will strive to build a high-quality and efficient traditional Chinese medicine service system
Time of Update: 2022-04-18
The reporter learned from the State Administration of Traditional Chinese Medicine that during the "14th Five-Year Plan" period, China will further leverage the advantages of holistic medicine and health medicine of traditional Chinese medicine, and strive to promote the establishment of a traditional Chinese medicine service system that integrates preventive health care, disease treatment and rehabilitation .
-
92 varieties are on display!
Time of Update: 2022-04-18
com, the terminal competition pattern of public hospitals in key provinces and cities Pertuzumab injection leads the sales of nearly 1 billion yuan, which is Roche A new type of anti-HER2 drug developed by the company, which produces anti-HER2 effects by inhibiting HER2 heterologous and homodimers, was approved for import in December 2018 for the adjuvant treatment of patients with HER2-positive early breast cancer .
-
The four types of monitoring drug sales policies are loosened!
Time of Update: 2022-04-18
In order to strengthen the prevention and control of the new crown pneumonia epidemic, in early 2020, Guangdong Province took the lead in requiring all retail pharmacies to implement a registration and reporting system when selling fever and cough medicines.
-
After years of low prices, the price of mulberry and white skin is rising step by step!
Time of Update: 2022-04-18
2. It is difficult to supply high-quality goods, and the price rises: 2017-2022 market price trend of mulberry white skin.
The supply of high-quality wild mulberry and white bark is decreasing year by year, while the export volume has increased in recent years, and the market has gradually risen .
-
The two ministries jointly issued the "Quality Management Specification for Clinical Trials of Medical Devices"
Time of Update: 2022-04-18
On March 31, the State Food and Drug Administration issued an announcement stating that in order to deepen the reform of the medical device review and approval system and strengthen the management of
-
10 departments including the State Administration of Traditional Chinese Medicine: By 2025, community health service centers and traditional Chinese medicine clinics in township health centers will achieve full coverage
Time of Update: 2022-04-18
According to news from the website of the State Administration of Traditional Chinese Medicine on the 30th, 10 departments including the State Administration of Traditional Chinese Medicine jointly i
-
National Health Commission: During the "14th Five-Year Plan" period, efforts will be made to build key clinical specialty groups
Time of Update: 2022-04-18
During the "14th Five-Year Plan" period, China will focus on promoting the improvement of diagnosis and treatment capabilities through the development of specialties, and support provinces to build no less than 750 national key clinical specialty construction projects .
-
The "14th Five-Year Plan for the Development of Traditional Chinese Medicine" was issued to improve the price of traditional Chinese medicine and medical insurance policies
Time of Update: 2022-04-18
Remove institutional and policy obstacles, improve policy measures and evaluation standard systems, continue to promote reform and innovation in the field of traditional Chinese medicine, establish a service system, service model, management model, and talent training model that conform to the characteristics of traditional Chinese medicine, and promote high-quality traditional Chinese medicine business and industry.
-
The total cost of antigen testing in Beijing shall not exceed 11.37 yuan per time. 19 provinces specify the maximum price
Time of Update: 2022-04-18
According to the Beijing Municipal Medical Security Bureau, since March 25, Beijing has temporarily included the new coronavirus antigen detection reagents and corresponding detection items into the catalogue of basic medical insurance medical service items, and listed them as Category A items, which will be paid by the medical insurance fund according to regulations.
-
Fully assist the intelligent construction of the elderly care industry, settle down and then appear on CCTV!
Time of Update: 2022-04-17
As early as October 2020 , Anton was selected into the "Smart and Healthy Elderly Care Products and Services Promotion Catalog ( 2020 Edition)" jointly formulated by the Ministry of Industry and Information Technology, the Ministry of Civil Affairs, and the Health and Health Commission .
